HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Seeds OTC Growth Synergies With Former Allergan Business

This article was originally published in The Pink Sheet

Executive Summary

Teva's opportunity to compete in the US OTC drug market now that the Allergan's generic nonprescription products are under its roof makes company "more excited" about the space "than we have ever been," says CEO Sigurdur Olaf Olaffson,

You may also be interested in...



Teva’s 'Key Ingredient' For Growth: Biosimilars

Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.

Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says

'I can't wait until it's over,' Teva's Generic Medicines CEO Sigurdur Olafsson said of the US Presidential election; then the current debate around drug pricing will return to a discussion of value, he predicted.

Private Label Mucinex March Reaches Two Formulations

Perrigo starts first shipments of a 1,200mg guaifenesin/60mg DXM generic of Mucinex DM, indicated to control coughs and to break up mucus.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS123160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel